Your Article Summary
Systemic chemotherapy for bladder cancer
Der Urologe, 07/02/09
Retz M et al. - This review summarizes the results of first-line and second-line systemic chemotherapy for advanced urothelial carcinoma as well as data from adjuvant and neoadjuvant trials for locally advanced bladder cancer. Whereas conventional systemic chemotherapy prevailed for over two decades, targeted therapeutics have been introduced to treat urothelial cancer during recent years.
Related Articles
A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma
Cancer, 11/09/09
Relevance Score: 92%
Effectiveness of Traditional Chinese Medicine for Liver Protection and Chemotherapy Completion among Cancer Patients
Evidence-based Complementary and Alternative Medicine, 11/20/09
Relevance Score: 91%
Selective internal radiation therapy for liver metastases from colorectal cancer
Cochrane Reviews, 10/09/09
Relevance Score: 91%
Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial
The Lancet Oncology - Online First, 10/30/09
Relevance Score: 90%
Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy
Cancer, 10/20/09
Relevance Score: 90%
Today in Bladder...keeping you current
Receive free subspecialty "5-minute updates" via email
A MicroRNA expression profile defining the invasive bladder tumor phenotype
Urologic Oncology: Seminars and Original Investigations, 12/18/09
Combination of vesicoureteric reflux and vesicoureteric junction obstruction
Scandinavian Journal of Urology and Nephrology, 12/18/09
Behavioral Intervention versus Pharmacotherapy or Their Combinations in the Management of Overactive Bladder Dysfunction
Advances in Urology, 12/18/09
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase I trial with a combination of docetaxel and 153Sm-lexidronam in patients with castration-resistant metastatic prostate cancer
Urologic Oncology: Seminars and Original Investigations, 12/18/09
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
Clinical Cancer Research, 12/18/09
Oral Chemotherapy in Hormone-Refractory Prostate Carcinoma Patients Unwilling to Be Admitted to Hospital
Urologia Internationalis, 12/18/09
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
High DNA Methyltransferase 3B Expression Mediates 5-Aza-Deoxycytidine Hypersensitivity in Testicular Germ Cell Tumors
Cancer Research, 12/18/09
Phase I trial with a combination of docetaxel and 153Sm-lexidronam in patients with castration-resistant metastatic prostate cancer
Urologic Oncology: Seminars and Original Investigations, 12/18/09
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
Clinical Cancer Research, 12/18/09

See Latest Articles